Cardiac Marker Analyzer Market Outlook 2018-2023 - Rising Prevalence of Cardiovascular Diseases is Propelling Growth - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Aug 3, 2018--The “Cardiac Marker Analyzer Market - Forecasts from 2018 to 2023” report has been added to ResearchAndMarkets.com’s offering.
Cardiac marker analyzer market was valued at US$1,356.125 million in 2017 and is projected to expand at a CAGR of 4.84% over the forecast period to reach US$1,800.905 million by 2023.
Rising prevalence of cardiovascular diseases owing to growing global geriatric population and lifestyle-related diseases is driving the demand for cardiac marker analyzers worldwide.
Rising investments in R&D to develop innovative applications of cardiac marker analyzers and ongoing clinical trials to identify novel cardiac biomarkers will further fuel the growth of cardiac biomarker analyzer market.
However, factors such as technical problems related to sample collection and regulatory and reimbursement issues are restraining the growth of cardiac marker analyzer market.
Geographically, APAC will witness a significant market growth owing to the increasing cases of cardiovascular diseases and booming medical tourism industry, particularly in Southeast Asian countries.
Key Topics Covered
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.6. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Force Analysis
4.6. Product Pipeline
4.7. Life Cycle Analysis - Regional Snapshot
4.8. Market Attractiveness
5. CARDIAC MARKER ANALYZER MARKET BY TYPE OF CARDIAC MARKER
5.2. Creatine Kinase
6. CARDIAC MARKER ANALYZER MARKET BY END USER
6.1. Hospitals and Clinics
6.3. Ambulatory Surgical Centers
7. CARDIAC MARKER ANALYZER MARKET BY GEOGRAPHY
7.1. North America
7.2. South America
7.4. Middle East and Africa
8. COMPETITIVE INTELLIGENCE
8.1. Recent Deals and Investment
8.2. Strategies of Key Players
8.3. Investment Analysis
9. COMPANY PROFILES
9.1. Radiometer Medical APS
9.2. CardioGenics Inc.
9.3. Roche Diagnostics International Ltd
9.4. Abbott Rapid Diagnostics
9.5. Beckman Coulter, Inc.
9.6. Siemens Healthcare GmbH
9.7. LSI Medience Corporation
For more information about this report visit https://www.researchandmarkets.com/research/hgshvn/cardiac_marker?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180803005509/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CARDIOLOGY
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 08/03/2018 04:09 PM/DISC: 08/03/2018 04:09 PM